Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25

Core Insights - Coloplast reported a 6% organic growth in Q2, affected by a product recall in Interventional Urology and a softer performance in Ostomy Care [1][3] - The company maintained an EBIT margin of 27% in Q2, with reported revenue in DKK increasing by 5% [1][2] - The FY 2024/25 guidance has been revised to an expected organic growth of around 7% and an EBIT margin before special items of 27-28% [3][7] Financial Performance - H1 2024/25 organic growth was 7%, with reported revenue in DKK reaching DKK 13,956 million, a 6% increase [2] - EBIT for the period was DKK 1,891 million, reflecting a 6% increase from the previous year, maintaining an EBIT margin of 27% [4] - Adjusted net profit before special items was DKK 2,666 million, a DKK 175 million increase from last year, with adjusted diluted EPS rising by 7% to DKK 11.83 [4] Business Area Performance - Organic growth rates by business area included: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10%, and Interventional Urology -1% [4] - The slower growth in Ostomy Care was attributed to a high baseline in Europe and tender phasing in Emerging markets, with expectations for improvement in the second half of the year [4] - Kerecis experienced a significant growth of 30%, with a 12% EBIT margin before PPA amortization [4] Strategic Changes - CEO Kristian Villumsen stepped down on 5 May 2025, with Lars Rasmussen appointed as interim CEO [5] - The Board is conducting a search for a new CEO to drive long-term growth and value creation [5] Future Outlook - The reported growth in DKK is now expected to be around 4%, down from previously around 7%, influenced by the revised organic growth outlook and currency impacts [7] - Special items are anticipated to be around DKK 450 million due to restructuring initiatives aimed at profitability improvement [7]